This case suggests that targeting the VEGF/VEGFR signaling pathway may be an essential new therapeutic choice for <i>TFE3</i>-associated malignant PEComas. The gene discussed is TFE3; the disease is neoplasm with perivascular epithelioid cell differentiation.